A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis.

Flavio Vincenti,Fernando C Fervenza,Kirk N Campbell,Montserrat Diaz,Loreto Gesualdo,Peter Nelson,Manuel Praga,Jai Radhakrishnan,Lorenz Sellin,Ajay Singh,Denyse Thornley-Brown,Francisco Veríssimo Veronese, Beverly Accomando, Sara Engstrand,Steven Ledbetter,Julie Lin,John Neylan,James Tumlin

Kidney International Reports（2017）

引用 93|浏览47

暂无评分

摘要

The study was underpowered and did not meet the primary or secondary endpoints. However, fresolimumab was well tolerated and is appropriate for continued evaluation in larger studies with adequate power.

查看译文

关键词

fresolimumab,monoclonal antibody,proteinuria,steroid-resistant primary focal segmental glomerulosclerosis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要